LYRA
Lyra Therapeutics, Inc.
Price Chart
Latest Quote
$0.58
+0.02 (+4.11%)
Current Price
| Previous Close | $0.56 |
| Open | $0.55 |
| Day High | $0.55 |
| Day Low | $0.55 |
| Volume | 5 |
Stock Information
| Shares Outstanding | 1.77M |
| Total Debt | $30.26M |
| Cash Equivalents | $15.89M |
| Revenue | $398K |
| Net Income | $-28.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.03M |
| EPS (TTM) | $-18.62 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.40M |
| Sales | $398K |
| Income | $-28.92M |
| Book/sh | $-6.04 |
| Cash/sh | $8.95 |
| Employees | 27 |
Financial Ratios
| Quick Ratio | 1.67 |
| Current Ratio | 1.71 |
Returns & Margins
| ROA | -36.06% |
| ROE | -6594.98% |
| Gross Margin | -152.76% |
| Operating Margin | -98728.57% |
Ownership
| Insider Ownership | 0.62% |
| Institutional Ownership | 13.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.59 |
| P/S | 2.60 |
| P/B | -0.10 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.67 |
| SMA50 | $0.70 |
| SMA200 | $2.82 |
| RSI | 44.37 |
| ATR | 0.0999 |
| Shares Float | 336K |
| Short Float | 1.10% |
| Short Ratio | 0.35 |
| Volatility | 0.69 |
| Rel Volume | 0.02 |
Performance History
| Week | -15.51% |
| Month | -22.27% |
| Quarter | +18.93% |
| 6 Months | -83.81% |
| YTD | -81.55% |
| Year | -94.93% |
| 3 Years | -99.62% |
| 5 Years | -99.87% |
| 10 Years | -99.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.58 | 297 |
| 2026-06-23 | $0.56 | 10,725 |
| 2026-06-22 | $0.57 | 84,579 |
| 2026-06-18 | $0.68 | 232 |
| 2026-06-17 | $0.69 | 0 |
| 2026-06-16 | $0.69 | 1,377 |
| 2026-06-15 | $0.65 | 3,622 |
| 2026-06-12 | $0.55 | 40,506 |
| 2026-06-11 | $0.60 | 3,102 |
| 2026-06-10 | $0.60 | 88,159 |
| 2026-06-09 | $0.80 | 2,058 |
| 2026-06-08 | $0.70 | 5,288 |
| 2026-06-05 | $0.70 | 1,058 |
| 2026-06-04 | $0.69 | 11,097 |
| 2026-06-03 | $0.66 | 20,831 |
| 2026-06-02 | $0.70 | 4,131 |
| 2026-06-01 | $0.70 | 1,842 |
| 2026-05-29 | $0.74 | 2,752 |
| 2026-05-28 | $0.70 | 1,278 |
| 2026-05-27 | $0.78 | 6,131 |
| 2026-05-26 | $0.70 | 3,159 |
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Lyra Therapeutics suspends further development of LYR-210
TipRanks âĸ 2026-01-13T12:26:31Z
Top Midday Decliners
MT Newswires âĸ 2026-01-12T20:18:03ZAssertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
Zacks âĸ 2025-11-10T22:45:02Z
Dentsply International (XRAY) Lags Q3 Earnings Estimates
Zacks âĸ 2025-11-06T14:15:05Z
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-04T14:15:02Z
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2025-08-12T21:15:03Z
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-08T12:55:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $1,534,000 | $1,558,000 | $1,363,000 | $285,000 |
| Operating Revenue | $1,534,000 | $1,558,000 | $1,363,000 | $285,000 |
| Expenses | ||||
| Total Expenses | $62,267,000 | $67,086,000 | $56,353,000 | $43,900,000 |
| Other Income Expense | $-35,615,000 | $-1,592,000 | $-1,316,000 | - |
| Net Non Operating Interest Income Expense | $2,952,000 | $4,499,000 | $1,041,000 | $102,000 |
| Operating Expense | $62,267,000 | $67,086,000 | $56,353,000 | $43,900,000 |
| General And Administrative Expense | $18,501,000 | $19,057,000 | $17,556,000 | $14,206,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Net Interest Income | $2,952,000 | $4,499,000 | $1,041,000 | $102,000 |
| Interest Income | $2,952,000 | $4,499,000 | $1,041,000 | $102,000 |
| Normalized Income | $-57,820,000 | $-61,088,000 | $-54,238,360 | $-43,513,000 |
| Net Income From Continuing And Discontinued Operation | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Total Operating Income As Reported | $-96,348,000 | $-67,120,000 | $-56,306,000 | $-43,615,000 |
| Net Income Common Stockholders | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Net Income | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Net Income Including Noncontrolling Interests | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Net Income Continuous Operations | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Pretax Income | $-93,396,000 | $-62,621,000 | $-55,265,000 | $-43,513,000 |
| Special Income Charges | $-35,615,000 | $-1,592,000 | $-1,316,000 | $0 |
| Interest Income Non Operating | $2,952,000 | $4,499,000 | $1,041,000 | $102,000 |
| Operating Income | $-60,733,000 | $-65,528,000 | $-54,990,000 | $-43,615,000 |
| Per Share | ||||
| Diluted EPS | $-71.50 | $-63.00 | $-91.50 | $-167.50 |
| Basic EPS | $-71.50 | $-63.00 | $-91.50 | $-167.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-276,360 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,647,000 | $-63,658,000 | $-52,607,000 | $-42,614,000 |
| Total Unusual Items | $-35,615,000 | $-1,592,000 | $-1,316,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-35,615,000 | $-1,592,000 | $-1,316,000 | $0 |
| Reconciled Depreciation | $471,000 | $278,000 | $1,067,000 | $1,001,000 |
| EBITDA (Bullshit earnings) | $-60,262,000 | $-65,250,000 | $-53,923,000 | $-42,614,000 |
| EBIT | $-60,733,000 | $-65,528,000 | $-54,990,000 | $-43,615,000 |
| Diluted Average Shares | $1,302,277 | $996,085 | $604,713 | $259,722 |
| Basic Average Shares | $1,302,277 | $996,085 | $604,713 | $259,722 |
| Diluted NI Availto Com Stockholders | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
| Tax Provision | $39,000 | $59,000 | $13,000 | $0 |
| Impairment Of Capital Assets | $24,719,000 | $1,592,000 | $1,316,000 | $0 |
| Restructuring And Mergern Acquisition | $10,896,000 | $0 | - | - |
| Research And Development | $43,766,000 | $48,029,000 | $38,797,000 | $29,694,000 |
| Selling General And Administration | $18,501,000 | $19,057,000 | $17,556,000 | $14,206,000 |
| Other Gand A | $18,501,000 | $19,057,000 | $17,556,000 | $14,206,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-03-11
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Total Assets | $66,346,000 | $142,600,000 | $109,968,000 | $54,867,000 |
| Total Non Current Assets | $23,321,000 | $37,779,000 | $9,139,000 | $6,949,000 |
| Other Non Current Assets | $1,993,000 | $2,503,000 | $4,673,000 | $1,091,000 |
| Current Assets | $43,025,000 | $104,821,000 | $100,829,000 | $47,918,000 |
| Other Current Assets | $2,448,000 | $2,068,000 | $2,935,000 | $2,171,000 |
| Cash Cash Equivalents And Short Term Investments | $40,577,000 | $102,753,000 | $97,894,000 | $45,747,000 |
| Cash And Cash Equivalents | $40,577,000 | $22,353,000 | $32,550,000 | $45,747,000 |
| Prepaid Assets | - | - | - | $2,171,000 |
| Debt | ||||
| Total Debt | $34,380,000 | $26,881,000 | $4,177,000 | $1,453,000 |
| Long Term Debt And Capital Lease Obligation | $30,259,000 | $21,447,000 | $667,000 | $379,000 |
| Current Debt And Capital Lease Obligation | $4,121,000 | $5,434,000 | $3,510,000 | $1,074,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $54,752,000 | $53,180,000 | $29,214,000 | $20,551,000 |
| Total Non Current Liabilities Net Minority Interest | $42,121,000 | $33,583,000 | $14,744,000 | $2,305,000 |
| Non Current Deferred Liabilities | $11,862,000 | $12,136,000 | $14,077,000 | $1,926,000 |
| Current Liabilities | $12,631,000 | $19,597,000 | $14,470,000 | $18,246,000 |
| Other Current Liabilities | $4,822,000 | $1,231,000 | $659,000 | $633,000 |
| Current Deferred Liabilities | $398,000 | $1,658,000 | $1,275,000 | $9,789,000 |
| Payables And Accrued Expenses | $3,290,000 | $11,274,000 | $9,026,000 | $6,750,000 |
| Payables | $1,179,000 | $3,131,000 | $2,616,000 | $3,125,000 |
| Accounts Payable | $1,179,000 | $3,131,000 | $2,616,000 | $3,125,000 |
| Equity | ||||
| Common Stock Equity | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Total Equity Gross Minority Interest | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Stockholders Equity | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $33,000 | $10,000 | $0 |
| Retained Earnings | $-404,790,000 | $-311,355,000 | $-248,675,000 | $-193,397,000 |
| Other Equity Adjustments | - | $33,000 | $10,000 | - |
| Other | ||||
| Ordinary Shares Number | $1,310,308 | $1,144,291 | $636,553 | $260,143 |
| Share Issued | $1,310,308 | $1,144,291 | $636,553 | $260,143 |
| Tangible Book Value | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Invested Capital | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Working Capital | $30,394,000 | $85,224,000 | $86,359,000 | $29,672,000 |
| Capital Lease Obligations | $34,380,000 | $26,881,000 | $4,177,000 | $1,453,000 |
| Total Capitalization | $11,594,000 | $89,420,000 | $80,754,000 | $34,316,000 |
| Additional Paid In Capital | $416,319,000 | $400,685,000 | $329,387,000 | $227,700,000 |
| Capital Stock | $65,000 | $57,000 | $32,000 | $13,000 |
| Common Stock | $65,000 | $57,000 | $32,000 | $13,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $11,862,000 | $12,136,000 | $14,077,000 | $1,926,000 |
| Long Term Capital Lease Obligation | $30,259,000 | $21,447,000 | $667,000 | $379,000 |
| Current Deferred Revenue | $398,000 | $1,658,000 | $1,275,000 | $9,789,000 |
| Current Capital Lease Obligation | $4,121,000 | $5,434,000 | $3,510,000 | $1,074,000 |
| Current Accrued Expenses | $2,111,000 | $8,143,000 | $6,410,000 | $3,625,000 |
| Net PPE | $21,328,000 | $35,276,000 | $4,466,000 | $5,858,000 |
| Accumulated Depreciation | $-4,129,000 | $-1,921,000 | $-4,174,000 | $-3,879,000 |
| Gross PPE | $25,457,000 | $37,197,000 | $8,640,000 | $9,737,000 |
| Leases | $486,000 | $461,000 | $397,000 | $2,113,000 |
| Other Properties | $23,851,000 | $35,969,000 | $7,245,000 | $6,648,000 |
| Machinery Furniture Equipment | $1,120,000 | $767,000 | $998,000 | $976,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $80,400,000 | $65,344,000 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $2,429,000 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-03-11
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-72,349,000 | $-64,351,000 | $-43,549,000 | $-29,205,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-70,011,000 | $-63,304,000 | $-43,385,000 | $-25,820,000 |
| Cash Flow From Continuing Operating Activities | $-70,011,000 | $-63,304,000 | $-43,385,000 | $-25,820,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,338,000 | $-1,047,000 | $-164,000 | $-3,385,000 |
| Investing Cash Flow | $80,305,000 | $-12,584,000 | $-65,006,000 | $-3,385,000 |
| Cash Flow From Continuing Investing Activities | $80,305,000 | $-12,584,000 | $-65,006,000 | $-3,385,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,818,000 | $69,242,000 | $100,495,000 | $0 |
| Financing Cash Flow | $8,531,000 | $65,691,000 | $96,257,000 | $359,000 |
| Cash Flow From Continuing Financing Activities | $8,531,000 | $65,691,000 | $96,257,000 | $359,000 |
| Net Other Financing Charges | $-290,000 | $-3,654,000 | $-4,246,000 | $-245,000 |
| Net Common Stock Issuance | $8,818,000 | $69,242,000 | $100,495,000 | $0 |
| Common Stock Issuance | $8,818,000 | $69,242,000 | $100,495,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $42,570,000 | $23,745,000 | $33,942,000 | $46,076,000 |
| Beginning Cash Position | $23,745,000 | $33,942,000 | $46,076,000 | $74,922,000 |
| Changes In Cash | $18,825,000 | $-10,197,000 | $-12,134,000 | $-28,846,000 |
| Proceeds From Stock Option Exercised | $3,000 | $103,000 | $8,000 | $604,000 |
| Net Investment Purchase And Sale | $82,643,000 | $-11,537,000 | $-64,842,000 | $0 |
| Sale Of Investment | $130,592,000 | $110,886,000 | $0 | - |
| Purchase Of Investment | $-47,949,000 | $-122,423,000 | $-64,842,000 | $0 |
| Net PPE Purchase And Sale | $-2,338,000 | $-1,047,000 | $-164,000 | $-3,385,000 |
| Purchase Of PPE | $-2,338,000 | $-1,047,000 | $-164,000 | $-3,385,000 |
| Change In Working Capital | $-6,346,000 | $-4,885,000 | $4,555,000 | $13,922,000 |
| Change In Other Working Capital | $-1,534,000 | $-1,558,000 | $3,637,000 | $11,715,000 |
| Change In Other Current Liabilities | $966,000 | $-1,208,000 | $763,000 | $-986,000 |
| Change In Other Current Assets | $2,464,000 | $-4,927,000 | $-1,442,000 | $446,000 |
| Change In Payables And Accrued Expense | $-7,862,000 | $1,941,000 | $2,361,000 | $3,594,000 |
| Change In Accrued Expense | $-5,975,000 | $1,491,000 | $4,772,000 | $1,244,000 |
| Change In Payable | $-1,887,000 | $450,000 | $-2,411,000 | $2,350,000 |
| Change In Account Payable | $-1,887,000 | $450,000 | $-2,411,000 | $2,350,000 |
| Change In Prepaid Assets | $-380,000 | $867,000 | $-764,000 | $-847,000 |
| Stock Based Compensation | $6,716,000 | $5,887,000 | $5,447,000 | $2,770,000 |
| Asset Impairment Charge | $24,859,000 | $1,592,000 | $1,316,000 | $0 |
| Amortization Of Securities | $-2,276,000 | $-3,496,000 | $-492,000 | $0 |
| Depreciation Amortization Depletion | $471,000 | $278,000 | $1,067,000 | $1,001,000 |
| Depreciation And Amortization | $471,000 | $278,000 | $1,067,000 | $1,001,000 |
| Depreciation | $471,000 | $278,000 | $1,067,000 | $1,001,000 |
| Net Income From Continuing Operations | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 |
Fetched: 2026-03-11